Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study

IF 4.7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Pub Date : 2026-03-28 Epub Date: 2026-02-24 DOI:10.1002/oby.70153

Haiyan Cheng, Xiao Jiang, Xiaowei Zhu, Xiaowen Zhu, Chenxi Li, Mengjiao Cao, Qunyan Zhou, Shukun Deng, Wenjun Wu

{"title":"Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study","authors":"Haiyan Cheng, Xiao Jiang, Xiaowei Zhu, Xiaowen Zhu, Chenxi Li, Mengjiao Cao, Qunyan Zhou, Shukun Deng, Wenjun Wu","doi":"10.1002/oby.70153","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This pilot study compared the effects of a calorie restricted diet (CRD) versus liraglutide on intrapancreatic fat deposition (IPFD) in people with obesity and explored associations between changes in adiposity-related metrics and glycemic-related parameters.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide. Primary endpoint was the change in pancreatic fat fraction (PFF). Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Both CRD (<i>n</i> = 23) and liraglutide (<i>n</i> = 23) demonstrated significant and comparable reductions in PFF (time effect: <i>p</i> < 0.001; interaction effect: <i>p</i> = 0.560). Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: <i>p</i> < 0.001; all interaction effects: <i>p</i> > 0.05). Regression analysis indicated that ΔHOMA2-IR was positively associated with Δweight and ΔLFF but negatively with ΔPFF, while ΔISIM was negatively associated with ΔVFA and positively with ΔPFF.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Both CRD and liraglutide significantly and similarly reduce pancreatic, liver, and visceral fat, while improving glycemic-related parameters in people with obesity. Preliminary findings suggest liver and visceral fat loss primarily drive improved insulin resistance, whereas pancreatic fat reduction may relate to subtler insulin dynamics changes, warranting further investigation.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>This study is a sub-study of the registered trial ChiCTR1900022948</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"829-838"},"PeriodicalIF":4.7000,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.70153","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This pilot study compared the effects of a calorie restricted diet (CRD) versus liraglutide on intrapancreatic fat deposition (IPFD) in people with obesity and explored associations between changes in adiposity-related metrics and glycemic-related parameters.

Methods

In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide. Primary endpoint was the change in pancreatic fat fraction (PFF). Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.

Results

Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560). Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p < 0.001; all interaction effects: p > 0.05). Regression analysis indicated that ΔHOMA2-IR was positively associated with Δweight and ΔLFF but negatively with ΔPFF, while ΔISIM was negatively associated with ΔVFA and positively with ΔPFF.

Conclusions

Both CRD and liraglutide significantly and similarly reduce pancreatic, liver, and visceral fat, while improving glycemic-related parameters in people with obesity. Preliminary findings suggest liver and visceral fat loss primarily drive improved insulin resistance, whereas pancreatic fat reduction may relate to subtler insulin dynamics changes, warranting further investigation.

Trial Registration

This study is a sub-study of the registered trial ChiCTR1900022948

查看原文本刊更多论文

热量限制饮食与利拉鲁肽对肥胖症患者胰腺内脂肪沉积的影响：一项初步研究。

目的：本初步研究比较了热量限制饮食（CRD）和利拉鲁肽对肥胖患者胰腺内脂肪沉积（IPFD）的影响，并探讨了肥胖相关指标和血糖相关参数变化之间的关系。方法：在这项为期24周的前瞻性非随机研究中，肥胖患者接受CRD或利拉鲁肽治疗。主要终点是胰腺脂肪分数（PFF）的变化。次要终点包括体重、肝脏脂肪分数（LFF）、内脏脂肪面积（VFA）和血糖相关参数的变化。结果：CRD （n = 23）和利拉鲁肽（n = 23）均能显著降低PFF（时间效应：p 0.05）。回归分析表明，ΔHOMA2-IR与Δweight、ΔLFF呈正相关，与ΔPFF呈负相关；ΔISIM与ΔVFA呈负相关，与ΔPFF呈正相关。结论：CRD和利拉鲁肽均能显著且相似地减少胰腺、肝脏和内脏脂肪，同时改善肥胖患者的血糖相关参数。初步研究结果表明，肝脏和内脏脂肪的减少主要驱动胰岛素抵抗的改善，而胰腺脂肪的减少可能与更微妙的胰岛素动力学变化有关，值得进一步研究。试验注册：本研究是已注册试验ChiCTR1900022948的子研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity 医学-内分泌学与代谢

CiteScore

11.70

自引率

1.40%

发文量

261

审稿时长

2-4 weeks

期刊介绍： Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.